Effective influenza vaccines for children: a critical unmet medical need and a public health priority.
Hum Vaccin Immunother
; 8(3): 398-402, 2012 Mar.
Article
in En
| MEDLINE
| ID: mdl-22327501
ABSTRACT
Seasonal influenza causes clinical illness and hospitalization in all age groups; however, conventional inactivated vaccines have only limited efficacy in young children. MF59(®), an oil-in-water emulsion adjuvant, has been used since the 1990s to enhance the immunogenicity of influenza vaccines in the elderly, a population with waning immune function due to immunosenescence. Clinical trials now provide information to support a favorable immunogenicity and safety profile of MF59-adjuvanted influenza vaccine in young children. Published data indicate that Fluad(®), a trivalent seasonal influenza vaccine with MF59, was immunogenic and well tolerated in young children, with a benefit/risk ratio that supports routine clinical use. A recent clinical trial also shows that Fluad provides high efficacy against PCR-confirmed influenza. Based on the results of clinical studies in children, the use of MF59-adjuvanted vaccine offers the potential to enhance efficacy and make vaccination a viable prevention and control strategy in this population.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines
/
Influenza, Human
Type of study:
Clinical_trials
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
/
Newborn
Language:
En
Journal:
Hum Vaccin Immunother
Year:
2012
Document type:
Article
Affiliation country:
Alemania